A41-16 Out of the Fire Into the Frying Pan: Everolimus-Induced Organizing Pneumonia in a Patient With Pancreatic Neuroendocrine Tumor

BACKGROUND Recently, mTOR inhibitors have emerged as key agents in the treatment of neuroendocrine tumors. Drug-induced pneumonitis is one of the most common causes of adverse drug events, unfortunately leading to treatment cessation. CASE REPORT We report a case of an 81-female with a history of hypertension, CKD, aortic stenosis, and pancreatic neuroendocrine tumor with metastatic liver disease who presented to the ED with persistent fatigue associated with exertional dyspnea, cough, and intermittent chest pain occurring after everolimus dose increase from 5mg to 7.5mg. She was placed on 1L of oxygen to relieve her dyspnea. Pulmonology team was consulted given CT findings concerning for bilateral lower lung multifocal opacities and left lower lobe consolidation, different compared to a recent PET scan. Dedicated CT scan showed organizing pneumonia pattern. She was empirically treated with IV azithromycin and ceftriaxone then discharged on PO amoxicillin-clavulanate with new requirement of 1L of oxygen at rest and 2L on exertion. Everolimus was held until outpatient bronchoscopy. BAL was negative for infectious workup. Cytology showed 10% eosinophil, with pathology confirming focal organizing pneumonia. Her respiratory symptoms and oxygen requirements improved after cessation of everolimus. She was eventually transitioned to cabozantinib instead. Discussion Low-threshold for suspicion of everolimus-induced pneumonitis in patients who present with respiratory symptoms after initiation or dose adjustment. Prompt diagnosis leads to avoidance of unnecessary antibiotics and immediate discontinuation and substitution of offending drug. Further research on adjunct therapy is recommended to avoid development of EIP in patients who urgently need therapy This abstract is funded by: none